Skip to main content

Table 2 ADHD symptom severity

From: Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine

Variable mean ( SD)

EUR group ( N=1217)

NE group ( N=800)

Total ( N=2017)

p-valuea

Standardized differences

CAARS-Inv:SV Score

    

  ADHD Index

24.7 (4.8)

22.8 (5.1)

23.9 (5.0)

<.0001

0.38

  Hyperactivity-Impulsivity Subscaleb

17.4 (5.2)

18.1 (5.0)

17.7 (5.1)

.0029

-0.137

  Inattention Subscaleb

20.9 (3.6)

21.4 (3.7)

21.1 (3.7)

.0008

-0.135

  Total ADHD Symptomb

38.3 (6.7)

39.6 (7.0)

38.8 (6.8)

<.0001

-0.191

CGI-ADHD-S Score

5.2 (0.8)

4.7 (0.7)

5.0 (0.8)

<.0001

0.625

AAQoL

    

  Abbreviated Total Scoreb

47.6 (14.3)

48.4 (14.1)

47.9 (14.2)

.2035

-0.056

  Psychological Health Section Score

51.4 (20.9)

52.5 (19.8)

51.9 (20.5)

.2379

-0.054

  Relationships Section Score

53.6 (21.2)

53.7 (19.2)

53.6 (20.4)

.9101

-0.005

  Life Outlook Section Score

45.1 (17.0)

52.5 (15.5)

48.1 (16.8)

<.0001

-0.440

  Life Productivity Section Score

44.2 (18.1)

41.2 (19.1)

43.0 (18.6)

.0004

0.161

EQ-5D

    

  UK Population-Based Index Score

0.80 (0.21)

0.84 (0.18)

0.82 (0.20)

.0003

-0.200

  US Population-Based Index Score

0.84 (0.14)

0.86 (0.13)

0.85 (0.14)

.0001

-0.143

Health State Score

70.0 (21.7)

75.6 (22.3)

72.2 (22.1)

<.0001

-0.253

  1. Abbreviations: ADHD = attention-deficit/hyperactivity disorder; AAQoL = adult ADHD quality of life; CAARS-Inv:SV = Conner’s adult ADHD rating scale-investigator rated: Screening Version; CGI-ADHD-S = clinical global impressions–ADHD-severity; EQ-5D = EuroQol-5 dimensions; EUR = European; N = total number of patients; NE = non-European; SD = standard deviation; UK = United Kingdom; US = United States.
  2. ap-values are from t-test.
  3. bimputed score.